ArticleOpen forum infectious diseases2019
Geographic and Temporal Patterns of Antimicrobial Resistance in
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026Review
- A Ten-Year Trend of Antimicrobial Resistance inOpen forum infectious diseases · 2026Article
- Beyond the Usual Suspects: EmergingInternational journal of molecular sciences · 2026Review
- Multidrug-resistant Pseudomonas aeruginosa in ICU patients and hospital surfaces: β-lactamase burden, biofilm formation and clonal spread.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico.Scientific reports · 2026Article
- Dramatic increase in consumption of antibiotics in Colombia, 2020-2023Biomedica : revista del Instituto Nacional de Salud · 2026Article
- Biological characterization of multidrug-resistantMicrobiology spectrum · 2026Article
- Comparative genomics of colistin-nonsusceptible multidrug-resistant Pseudomonas aeruginosa reveals emerging lineages in Thailand.Scientific reports · 2026Article
- Genetic Determinants Linked to MDR/XDR inPathogens (Basel, Switzerland) · 2026Article
- From burden to action: Saudi Arabia's strategy on antimicrobial resistance.Open medicine (Warsaw, Poland) · 2026Review
- Phylogenetic Analysis and In Vitro Antimicrobial Potential of Some Herbal Extracts Against Multidrug-ResistantJournal of tropical medicine · 2026Article
- Trends inAntibiotics (Basel, Switzerland) · 2025Article
- Epidemiological Trends of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Evolution of Resistant Mutants inMicroorganisms · 2025Article
- Genomic epidemiology and characterization of difficult-to-treat resistant Pseudomonas aeruginosa isolates co-harboring blaScientific reports · 2025Article
- Genomic Characterization of Extremely Antibiotic-Resistant Strains ofBiotech (Basel (Switzerland)) · 2025Article
- β-Lactamase diversity inAntimicrobial agents and chemotherapy · 2025Article
- Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-ResistantPharmaceuticals (Basel, Switzerland) · 2025Article
- Correlation between carbapenem susceptibility inAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe SENTRY Antimicrobial Surveillance Program was established in 1997 and encompasses over 750 000 bacterial isolates from ≥400 medical centers worldwide. Among the pathogens tested,
methodsFrom 1997 to 2016, 52 022 clinically significant consecutive isolates were submitted from ≥200 medical centers representing the Asia-Pacific region, Europe, Latin America, and North America. Only 1 isolate per patient per infection episode was submitted. Isolates were identified by standard algorithms and/or matrix-assisted laser desorption ionization-time of flight mass spectrometry. Susceptibility testing was performed by Clinical and Laboratory Standards Institute (CLSI) methods and interpreted using CLSI and European Committee on Antimicrobial Susceptibility Testing 2018 criteria at JMI Laboratories.
resultsThe most common infection from which
conclusionsOver the 20 years of SENTRY Program surveillance, the rate of MDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.